Department of Internal Medicine I, University Hospital Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Cardiovasc Diabetol. 2013 Aug 16;12:117. doi: 10.1186/1475-2840-12-117.
GLP-1 is an incretine hormone which gets secreted from intestinal L-cells in response to nutritional stimuli leading to pancreatic insulin secretion and suppression of glucagon release. GLP-1 further inhibits gastric motility and reduces appetite which in conjunction improves postprandial glucose metabolism. Additional vasoprotective effects have been described for GLP-1 in experimental models. Despite these vasoprotective actions, associations between endogenous levels of GLP-1 and cardiovascular disease have yet not been investigated in humans which was the aim of the present study.
GLP-1 serum levels were assessed in a cohort of 303 patients receiving coronary CT-angiography due to typical or atypical chest pain.
GLP-1 was found to be positively associated with total coronary plaque burden in a fully adjusted model containing age, sex, BMI, hypertension, diabetes mellitus, smoking, triglycerides, LDL-C (low density lipoprotein cholesterol), hsCRP (high-sensitive C-reactive protein), and eGFR (estimated glomerular filtration rate) (OR: 2.53 (95% CI: 1.12 - 6.08; p = 0.03).
Circulating GLP-1 was found to be positivity associated with coronary atherosclerosis in humans. The clinical relevance of this observation needs further investigations.
GLP-1 是一种肠促胰岛素激素,在营养刺激下从肠 L 细胞分泌,导致胰腺胰岛素分泌和胰高血糖素释放抑制。GLP-1 进一步抑制胃动力,减少食欲,从而改善餐后葡萄糖代谢。在实验模型中还描述了 GLP-1 的额外血管保护作用。尽管有这些血管保护作用,但在人类中尚未研究内源性 GLP-1 水平与心血管疾病之间的关系,这也是本研究的目的。
在因典型或非典型胸痛而接受冠状动脉 CT 血管造影的 303 例患者队列中评估了 GLP-1 的血清水平。
在包含年龄、性别、BMI、高血压、糖尿病、吸烟、甘油三酯、LDL-C(低密度脂蛋白胆固醇)、hsCRP(高敏 C 反应蛋白)和 eGFR(估计肾小球滤过率)的完全调整模型中,GLP-1 与总冠状动脉斑块负担呈正相关(OR:2.53(95%CI:1.12-6.08;p=0.03)。
在人类中发现循环 GLP-1 与冠状动脉粥样硬化呈正相关。这种观察的临床意义需要进一步研究。